Guide to EU Pharmaceutical Regulatory Law -4th edition
|
|||||||||||||
|
|
|||||||||||||
Editor: Sally Shorthose, Bird & Bird LLP In the European Union and its Member States, as elsewhere, the marketing of pharmaceuticals has become subject to an increasingly complex web of legislation and regulation, resulting from the intense scrutiny necessary to ensure such essential products are not only efficacious but safe. This useful volume lays out this system with extraordinary clarity and logic. Adopting a Europe-wide perspective on the law governing pharmaceuticals, expert authors from the law firm Bird & Bird LLP map the life cycle of a medicinal product or medical device from development to clinical trials to product launch and ongoing pharmacovigilance, offering comprehensive and unambiguous guidance at every stage. Following an introductory overview focusing on the regulatory framework for pharmaceuticals in Europe – from its underlying rationales to the relevant committees and agencies – each of seventeen incisive chapters examines a particular process or subject. Among the many topics and issues covered are the following: • obtaining a marketing authorisation; In addition, national variation charts in many of the chapters illustrate eight major jurisdictions (Belgium, France, Germany, Italy, The Netherlands, Spain, Sweden, and the UK). Sample forms and URLs for the most important Directives are included. Pharmaceutical lawyers and regulatory advisers, both in-house and in private practice, will welcome this unique book. It offers immeasurable value for all who need to understand the process of bringing a medicinal product or medical device to market and the continuing rights and obligations. This fourth edition updates each chapter, including references to recent case law regulatory updates and in the section on clinical trials, a review and analysis of the anticipated major developments in this area. Price: EUR 253.00 / USD 341.00 / GBP 202.00 Ordering:
|
|||||||||||||